Prabhudas Lilladher has come out with its third quarter (October-December’ 20) earnings estimates for the Pharma sector. The brokerage house expects Jubilant Life Sciences to report net profit at Rs. 238 crore up 14.9% year-on-year (up 22% quarter-on-quarter).
Net Sales are expected to increase by 10.4 percent Y-o-Y (up 7.6 percent Q-o-Q) to Rs. 2,315.2 crore, according to Prabhudas Lilladher.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 0.1 percent Y-o-Y (up 4.5 percent Q-o-Q) to Rs. 507.4 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Read More
